Online citations, reference lists, and bibliographies.

Pharmacologic Prevention Of Venous Thromboembolism In Obese Patients

Kamila Bakirhan, Marianna Strakhan
Published 2012 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Venous thromboembolism, a collective term for pulmonary embolism and deep venous thrombosis accounts for a large amount of mortality and morbidity in hospitalized patients. Obesity has been considered as an important risk factor for the development of venous thromboembolism. Anticoagulation with fixed doses of low molecular weight heparin, anti-factor Xa inhibitors and unfractionated heparin is widely used in hospitals and has shown to be an effective measure in prevention of venous thromboembolism in multiple major randomized, double-blind controlled trials. Appropriate dosing of anticoagulation in obese patients is still controversial, since obese and morbidly obese population of patients is consistently underrepresented or often excluded from most clinical trials, raising a concern for adequacy of standard dosing in this high risk population.
This paper references
10.1007/s002280000141
The effect of body weight on dalteparin pharmacokinetics A preliminary study
Justin Y Yee (2000)
10.1126/science.281.5383.1683
Biological action of leptin as an angiogenic factor.
M Rocío Sierra-Honigmann (1998)
Risk factors for venous thromboembolism. Circulation 107(23 Suppl 1):I9–I16
Anderson FA (2003)
10.1378/chest.11-2297
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only ArticlesPrevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Ches
Michael K. Gould (2012)
10.1046/j.1365-2796.1999.00472.x
Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women.
Stefan Söderberg (1999)
10.2165/11599410-000000000-00000
Impact of Obesity on Drug Metabolism and Elimination in Adults and Children
Margreke J. E. Brill (2012)
10.1016/j.amjmed.2005.03.012
Obesity as a risk factor in venous thromboembolism.
Paul D. Stein (2005)
10.1016/j.thromres.2009.02.003
Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients.
Matthew T Rondina (2010)
Physicians evidence - based clinical practice guidelines
EA Nutescu (2009)
10.1016/S0140-6736(07)60633-3
The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison
D. George Sherman (2007)
10.1381/09608920160558588
Prophylaxis of Venous Thromboembolism Using Two Different Doses of Low-Molecular-Weight Heparin (Nadroparin) in Bariatric Surgery: A Prospective Randomized Trial
Fotis Kalfarentzos (2001)
10.1016/S0272-5231(02)00077-1
Risk factors for venous thromboembolism.
John A Heit (2003)
10.1002/bjs.4068
Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients.
Sven G Frederiksen (2003)
10.1038/ncpcardio0380
Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease
Yuji Matsuzawa (2006)
10.1053/j.ackd.2010.05.010
Estimating the glomerular filtration rate in obese adult patients for drug dosing.
Manjunath P Pai (2010)
10.1056/NEJMoa1006885
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
Michael Rud Lassen (2010)
10.1016/0140-6736(91)91573-D
Influence of skinfold thickness on heparin absorption
Caroline Kroon (1991)
10.1160/TH08-07-0493
Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
Sorrel E. Wolowacz (2008)
10.1381/096089205774859245
Enoxaparin for Thromboprophylaxis in Morbidly Obese Patients Undergoing Bariatric Surgery: Findings of the Prophylaxis Against VTE Outcomes in Bariatric Surgery Patients Receiving Enoxaparin (PROBE) Study
Giselle G. Hamad (2005)
10.1381/096089204323093354
Unfractionated Heparin Infusion for Thromboprophylaxis in Highest Risk Gastric Bypass Surgery
Michele F.Shepherd (2004)
10.1136/bmj.38733.466748.7C
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial
Alexander A. Cohen (2006)
10.1056/NEJM199909093411103
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Meyer Michel Samama (1999)
10.1016/0741-5214(92)90225-W
Physician practices in the management of venous thromboembolism: a community-wide survey.
Fred A. Anderson (1992)
10.1055/s-0037-1616243
The epidemiology of venous thromboembolism in the community.
John A Heit (2001)
10.2165/00003088-200039030-00004
Effects of Obesity on Pharmacokinetics
Georges Cheymol (2000)
10.1007/s11695-011-0397-y
Evaluating the Safety and Efficacy of BMI-Based Preoperative Administration of Low-Molecular-Weight Heparin in Morbidly Obese Patients Undergoing Roux-en-Y Gastric Bypass Surgery
Kuldeep Singh (2011)
10.1111/j.1472-8206.1988.tb00635.x
Drug pharmacokinetics in the obese.
Georges Cheymol (1988)
10.1381/096089205774512528
Continuous Intravenous Heparin Infusion Prevents Peri-operative Thromboembolic Events in Bariatric Surgery Patients
Brian B. Quebbemann (2005)
10.1016/j.thromres.2011.10.021
Thrombosis and obesity: cellular bases.
Roberto Lorenzet (2012)
10.1056/NEJMoa0810773
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
Michael Rud Lassen (2009)
10.1042/cs0910679
Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity.
Lucinda K M Summers (1996)
Lowmolecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings
EA Nutescu (2009)
10.1182/blood.V98.12.3353
Regulation of tissue factor gene expression in obesity.
Fahumiya Samad (2001)
Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and
Holger J. Schünemann (2008)
10.1001/jama.2009.2014
Prevalence and trends in obesity among US adults, 1999-2008.
Katherine M. Flegal (2010)
10.1161/01.cir.0000138928.83266.24
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Alain Leizorovicz (2004)
10.1016/j.mce.2009.08.006
Angiogenesis and development of adipose tissue
Valerie Christiaens (2010)
10.1016/j.soard.2007.11.010
Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
Marilyn J. Borkgren-Okonek (2008)
10.2174/138920011794520035
Does hepatic steatosis affect drug metabolizing enzymes in the liver?
Christa Buechler (2011)
10.1016/0049-3848(92)90213-T
Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin Study Group.
Lucienne Bara (1992)
10.1007/s11695-007-9381-y
Anti-Xa Levels in Bariatric Surgery Patients Receiving Prophylactic Enoxaparin
Brea O Rowan (2008)
10.2165/11318100-000000000-00000
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
Michael J. Hanley (2010)
10.2337/db06-1656
Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans
Luigi Fontana (2007)
10.1016/S0140-6736(09)62125-5
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
Michael Rud Lassen (2010)
10.1016/j.numecd.2009.01.006
Platelet dysfunction in central obesity.
Giovanni Anfossi (2009)
10.1055/s-0037-1613090
Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.
James W. Hainer (2002)
10.1378/chest.10-3084
Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis.
Olivia J. Phung (2011)
10.1111/j.1365-2125.1983.tb02258.x
Serum alpha 1-acid glycoprotein and the binding of drugs in obesity.
Irma H. Benedek (1983)
10.7326/0003-4819-119-9-199311010-00002
The Weight-based Heparin Dosing Nomogram Compared with a Standard Care Nomogram
Robert A Raschke (1993)
10.2146/ajhp110010
Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity.
Larissa A Martinez (2011)
10.1055/s-0038-1653139
Prevention Of Deep Vein Thrombosis In Medical Patients By Low Dose Subcutaneous Heparin
Jill J. F. Belch (1981)
10.1160/TH10-09-0601
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
Alexander G. G. Turpie (2011)
Physicians evidence - based clinical practice guidelines
AC Spyropoulos (2009)
10.1001/archsurg.135.12.1410
Factor V leiden and morbid obesity in fatal postoperative pulmonary embolism.
Hagan Blaszyk (2000)
10.1056/nejm200012283432613
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.
P Hari (2000)
10.1016/j.amjmed.2009.04.027
Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives.
Alex C Spyropoulos (2009)
10.1016/S1579-2129(09)60003-3
[Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass].
David Jiménez (2008)
10.1067/mcp.2002.127114
The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers.
Ger-Jan C M Sanderink (2002)
10.1378/chest.11-2292
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Walter Ageno (2012)
10.2165/00003088-200241002-00001
The Pharmacokinetics of Fondaparinux Sodium in Healthy Volunteers
François Donat (2002)
10.1001/archinte.168.15.1678
Overweight, obesity, and the risk of recurrent venous thromboembolism.
Sabine Eichinger (2008)
10.1038/sj.clpt.6100381
Dosing in obesity: a simple solution to a big problem.
Phey Yen Han (2007)
10.1111/j.1467-789X.2009.00593.x
Role of adipose tissue in haemostasis, coagulation and fibrinolysis.
Daniël R Faber (2009)
10.1001/archinte.165.3.341
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.
Nils Kucher (2005)
10.1055/s-2002-32312
Venous thromboembolism epidemiology: implications for prevention and management.
John A Heit (2002)
10.1152/physrev.00017.2007
Cardiac remodeling in obesity.
Eleanor Abel (2008)
The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers.
Kishor M. Wasan (1993)
10.1381/096089297765555575
The Incidence of Clinical Postoperative Thrombosis After Gastric Surgery for Obesity During 16 Years
Staffan Eriksson (1997)
Influence of obesity on drug disposition.
Robert A. Blouin (1987)
10.1016/j.ejvs.2006.10.006
Obesity and thrombosis.
Katy A L Darvall (2007)
10.1001/archinte.162.16.1833
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Alexander G. G. Turpie (2002)
Physicians Evidence - Based Clinical Practice Guidelines
SE Wolowacz (2009)
10.2165/00003088-200847030-00006
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery
Wolfgang Mueck (2008)
10.1016/j.thromres.2011.10.037
Fondaparinux - data on efficacy and safety in special situations.
Michael Nagler (2012)
10.1007/s00464-008-9997-6
Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery
Erin P. Simone (2008)
10.1038/oby.2009.92
Prospective study of BMI and the risk of pulmonary embolism in women.
Christopher Kabrhel (2009)
10.1381/096089202321144522
A Comparison of Two Different Prophylactic Dose Regimens of Low Molecular Weight Heparin in Bariatric Surgery
Donald J. Scholten (2002)
10.1007/s11695-008-9738-x
Effect of Prophylactic Dalteparin on Anti-factor Xa Levels in Morbidly Obese Patients After Bariatric Surgery
M. Simoneau (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar